Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN AND HYDROCHLOROTHIAZIDE.
FILSPARI vs TELMISARTAN AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
200 mg orally once daily, with or without food.
Oral, one tablet once daily. Initial: Telmisartan 40 mg/HCTZ 12.5 mg; titrate to max 80 mg/25 mg once daily.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Telmisartan: 24 hours (terminal); supports once-daily dosing with ~3-5 days to steady state. Hydrochlorothiazide: 6-15 hours (mean 10h); prolonged in renal impairment.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Telmisartan: >99% biliary-fecal as unchanged drug, <2% renal. Hydrochlorothiazide: ≥95% renal as unchanged drug; minimal biliary.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB